<DOC>
	<DOC>NCT00657735</DOC>
	<brief_summary>The purpose of the study is to explore the efficacy and safety of H1-Coil deep brain rTMS in subjects with bipolar depression , currently treated with mood stabilizer and previously unsuccessfully treated with antidepressant medications</brief_summary>
	<brief_title>Double Blind Randomized Controlled, H1 Coil In Subjects With Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>• Outpatients Diagnosed by two senior psychiatrists as suffering from bipolar depression (BP1, BP2) episode according to DSM IV using the Structured Clinical Interview for DSM4 (SCID), with additional requirement of duration for the current episode ≥ 4 weeks and CGI ≥ 4. Rating on HAMD (17 items) &gt;20 and item 1 ≥2 at the screening visit. Age: 1865 years. Gave informed consent for participation in the study. Negative answers on safety screening questionnaire for transcranial magnetic stimulation Taking mood stabilizing medication (e.g., lithium) on an acceptable range of dosage according to recent blood examination or antipsychotic medication as mood stabilizers prescribed by their treating physician According to the treating physician the patient is compliant in taking the moodstabilizing medication. Medication resistance to at least two different antidepressant treatments, defined as resistance to a minimum of 2 antidepressant drug trials of adequate dose and duration in the current episode or previous episodes defined as a minimum level of 3 on the ATHF per antidepressant drugtrial. Patients who have not completed antidepressant trials of adequate dose and duration due to intolerance to therapy may be included if they have demonstrated intolerance to 3 or more antidepressant medications in the current or a previous episodes. If currently taking antidepressant pharmacotherapy, must be clinically appropriate to discontinue treatment with those agents. Able to tolerate psychotropic medication washout and no psychotropics during the Hcoil deep brain rTMS other than benzodiazepine at equivalent dose of up to 3 mg lorazepam every day. Right hand dominance. • Diagnosis as suffering from other diagnosis on axis 1 (like: schizophrenia, geriatric depression). Diagnosis as suffering from Severe Borderline Personality Disorder or hospitalized due to exacerbation related to of borderline personality disorder. Substantial suicidal risk as judged by the treating psychiatrist. Attempted suicide in the past year. Patients with a bipolar cycle of less than 30 days. History of epilepsy or seizure in first degree relatives. History of head injury. History of any metal in the head (outside the mouth). Known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, surgical clips or any medical pumps. History of frequent or severe headaches. History of migraine. History of hearing loss. Known history of cochlear implants History of substance abuse within the past 6 months (except nicotine and caffeine) or alcoholism Pregnancy or not using a reliable method of birth control. Unstable Systemic and metabolic disorders. Unstable neurological or medical disease Inadequate communication with the patient. Under custodial care. Participation in current clinical study or clinical study within 30 days prior to this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>bipolar</keyword>
	<keyword>depression</keyword>
	<keyword>prefrontal</keyword>
	<keyword>cortex</keyword>
	<keyword>antidepressant</keyword>
	<keyword>response</keyword>
</DOC>